Telesis Bio, Inc. (TBIO)
OTCMKTS
· Delayed Price · Currency is USD
0.0120
-0.0003 (-2.44%)
May 12, 2025, 4:00 PM EDT
Telesis Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 27.51 | 27.44 | 11.04 | 6.58 | 5.77 |
| Revenue Growth (YoY) | 0.27% | 148.44% | 67.93% | 14.05% | - |
| Cost of Revenue | 10.56 | 11.84 | 6.74 | 2.95 | 3.21 |
| Gross Profit | 16.95 | 15.6 | 4.3 | 3.63 | 2.55 |
| Selling, General & Admin | 34.6 | 38.62 | 24.91 | 11.06 | 6.94 |
| Research & Development | 17.5 | 23.46 | 14.47 | 8.93 | 3.98 |
| Operating Expenses | 52.1 | 62.08 | 39.37 | 19.99 | 10.92 |
| Operating Income | -35.15 | -46.49 | -35.07 | -16.36 | -8.37 |
| Interest Expense | -3.11 | -1.96 | -1.37 | -0.69 | -1.79 |
| Interest & Investment Income | 1.74 | 0.74 | - | - | - |
| Other Non Operating Income (Expenses) | 0.34 | -0.02 | -1.56 | -0.88 | 0.43 |
| EBT Excluding Unusual Items | -36.18 | -47.72 | -38 | -17.93 | -9.73 |
| Merger & Restructuring Charges | - | - | -0.3 | - | - |
| Impairment of Goodwill | -11.39 | - | - | - | - |
| Gain (Loss) on Sale of Assets | -0.14 | -0 | -0.03 | - | -0.23 |
| Asset Writedown | - | - | - | -0.07 | - |
| Other Unusual Items | - | -0.73 | -0.62 | - | - |
| Pretax Income | -47.7 | -48.45 | -38.94 | -18.01 | -9.96 |
| Income Tax Expense | 0.02 | 0.02 | 0.01 | 0.01 | - |
| Net Income | -47.72 | -48.47 | -38.96 | -18.01 | -9.96 |
| Preferred Dividends & Other Adjustments | 1.3 | - | - | - | - |
| Net Income to Common | -49.02 | -48.47 | -38.96 | -18.01 | -9.96 |
| Shares Outstanding (Basic) | 2 | 2 | 1 | 0 | 0 |
| Shares Outstanding (Diluted) | 2 | 2 | 1 | 0 | 0 |
| Shares Change (YoY) | 1.31% | 61.69% | 264.34% | 0.03% | - |
| EPS (Basic) | -29.56 | -29.61 | -38.48 | -64.82 | -35.86 |
| EPS (Diluted) | -29.56 | -29.61 | -38.48 | -64.82 | -35.86 |
| Free Cash Flow | -36.65 | -43.18 | -38.55 | -15.59 | -7.76 |
| Free Cash Flow Per Share | -22.10 | -26.38 | -38.08 | -56.09 | -27.95 |
| Gross Margin | 61.62% | 56.84% | 38.93% | 55.13% | 44.29% |
| Operating Margin | -127.78% | -169.44% | -317.61% | -248.80% | -145.18% |
| Profit Margin | -178.21% | -176.68% | -352.78% | -273.88% | -172.78% |
| Free Cash Flow Margin | -133.22% | -157.40% | -349.11% | -237.00% | -134.63% |
| EBITDA | -32.83 | -44.81 | -34.17 | -15.5 | -7.34 |
| EBITDA Margin | -119.34% | -163.35% | - | -235.63% | -127.35% |
| D&A For EBITDA | 2.32 | 1.67 | 0.91 | 0.87 | 1.03 |
| EBIT | -35.15 | -46.49 | -35.07 | -16.36 | -8.37 |
| EBIT Margin | -127.78% | -169.44% | - | -248.80% | -145.18% |
| Revenue as Reported | 27.51 | 27.44 | 11.04 | 6.58 | 5.77 |
| Advertising Expenses | 0.7 | 1 | 0.9 | 0.8 | - |
Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.